Cargando…

Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study

Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through the Rare Cancer Network (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23-86 years) with a male-to-female ratio o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ugurluer, Gamze, Miller, Robert C., Li, Yexiong, Thariat, Juliette, Ghadjar, Pirus, Schick, Ulrike, Ozsahin, Mahmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064304/
https://www.ncbi.nlm.nih.gov/pubmed/27746888
http://dx.doi.org/10.4081/rt.2016.6502
_version_ 1782460130853388288
author Ugurluer, Gamze
Miller, Robert C.
Li, Yexiong
Thariat, Juliette
Ghadjar, Pirus
Schick, Ulrike
Ozsahin, Mahmut
author_facet Ugurluer, Gamze
Miller, Robert C.
Li, Yexiong
Thariat, Juliette
Ghadjar, Pirus
Schick, Ulrike
Ozsahin, Mahmut
author_sort Ugurluer, Gamze
collection PubMed
description Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through the Rare Cancer Network (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23-86 years) with a male-to-female ratio of 1.9:1.0. Abdominal pain or discomfort was the most common presenting symptom. Regarding B-symptoms, 19.5% of patients had fever, 17.1% weight loss, and 9.8% night sweats. The most common radiological presentation was multiple lesions. Liver function tests were elevated in 56.1% of patients. The most common histopathological diagnosis was diffuse large B-cell lymphoma (65.9%). Most of the patients received Chop-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens; 4 patients received radiotherapy (dose range, 30.6-40.0 Gy). Median survival was 163 months, and 5- and 10-year overall survival rates were 77 and 59%, respectively. The 5- and 10-year disease-free and lymphoma-specific survival rates were 69, 56, 87 and 70%, respectively. Multivariate analysis revealed that fever, weight loss, and normal hemoglobin level were the independent factors influencing the outcome. In this retrospective multicenter RCN study, patients with PHL had a relatively better prognosis than that reported elsewhere. Multicenter prospective studies are still warranted to establish treatment guidelines, outcome, and prognostic factors.
format Online
Article
Text
id pubmed-5064304
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-50643042016-10-14 Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study Ugurluer, Gamze Miller, Robert C. Li, Yexiong Thariat, Juliette Ghadjar, Pirus Schick, Ulrike Ozsahin, Mahmut Rare Tumors Article Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through the Rare Cancer Network (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23-86 years) with a male-to-female ratio of 1.9:1.0. Abdominal pain or discomfort was the most common presenting symptom. Regarding B-symptoms, 19.5% of patients had fever, 17.1% weight loss, and 9.8% night sweats. The most common radiological presentation was multiple lesions. Liver function tests were elevated in 56.1% of patients. The most common histopathological diagnosis was diffuse large B-cell lymphoma (65.9%). Most of the patients received Chop-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens; 4 patients received radiotherapy (dose range, 30.6-40.0 Gy). Median survival was 163 months, and 5- and 10-year overall survival rates were 77 and 59%, respectively. The 5- and 10-year disease-free and lymphoma-specific survival rates were 69, 56, 87 and 70%, respectively. Multivariate analysis revealed that fever, weight loss, and normal hemoglobin level were the independent factors influencing the outcome. In this retrospective multicenter RCN study, patients with PHL had a relatively better prognosis than that reported elsewhere. Multicenter prospective studies are still warranted to establish treatment guidelines, outcome, and prognostic factors. PAGEPress Publications, Pavia, Italy 2016-10-06 /pmc/articles/PMC5064304/ /pubmed/27746888 http://dx.doi.org/10.4081/rt.2016.6502 Text en ©Copyright G. Ugurluer et al. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Ugurluer, Gamze
Miller, Robert C.
Li, Yexiong
Thariat, Juliette
Ghadjar, Pirus
Schick, Ulrike
Ozsahin, Mahmut
Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study
title Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study
title_full Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study
title_fullStr Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study
title_full_unstemmed Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study
title_short Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study
title_sort primary hepatic lymphoma: a retrospective, multicenter rare cancer network study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064304/
https://www.ncbi.nlm.nih.gov/pubmed/27746888
http://dx.doi.org/10.4081/rt.2016.6502
work_keys_str_mv AT ugurluergamze primaryhepaticlymphomaaretrospectivemulticenterrarecancernetworkstudy
AT millerrobertc primaryhepaticlymphomaaretrospectivemulticenterrarecancernetworkstudy
AT liyexiong primaryhepaticlymphomaaretrospectivemulticenterrarecancernetworkstudy
AT thariatjuliette primaryhepaticlymphomaaretrospectivemulticenterrarecancernetworkstudy
AT ghadjarpirus primaryhepaticlymphomaaretrospectivemulticenterrarecancernetworkstudy
AT schickulrike primaryhepaticlymphomaaretrospectivemulticenterrarecancernetworkstudy
AT ozsahinmahmut primaryhepaticlymphomaaretrospectivemulticenterrarecancernetworkstudy